| Today's Big NewsFeb 10, 2023 |
|
April 3 - 4, 2023 | San Diego, CA Connect with leading communications professionals and have honest, open discussions about how to develop your career in the industry. Early Bird Rate Ends February 10th.
|
|
| By James Waldron Confronted with safety findings, Aristea Therapeutics is not only canning work on its midstage inflammatory program but has decided to dissolve the business entirely. |
|
|
|
By Max Bayer AbbVie is setting the stage for an aggressive M&A push to fill the revenue vacuum left by Humira, with CEO Richard Gonzalez telling investors to expect a move if the shoe fits. |
By Max Bayer Blueprint Medicines' momentum has been stymied by a partial FDA clinical hold placed on its solid tumor prospect. The company announced that some patients have experienced visual adverse events, including light sensitivity and blurred vision. |
By Nick Paul Taylor After a long winter, the first signs of spring have brought the return of the lesser spotted upsized biotech IPO. Days after Structure Therapeutics closed its upsized offering, Mineralys Therapeutics has revealed a $192 million haul that positions it to race AstraZeneca to a new uncontrolled hypertension opportunity. |
|
Evaluating transporters is of critical importance because they assist in the movement of drugs into or out of cells and can therefore be heavily involved in drug interactions... Read More >>
|
|
By Nick Paul Taylor How many years of cash runway do biotechs need to feel comfortable? Two? Three? Eliem Therapeutics has decided its two years of cash looks dicey in the current capital environment—and has responded by shelving a phase 2-ready depression drug candidate and laying off 55% of staff in a pivot to preclinical. |
By Zoey Becker Not even six months after the U.S. Equal Employment Opportunity Commission sued Eli Lilly over alleged age bias, the company is at the center of another lawsuit. This one comes from an employee. |
By Andrea Park Titan Medical isn’t quite ready to give up on its robotic surgery technologies—even amid a possible delisting from the Nasdaq, widespread layoffs and a failed attempt at selling off the company. |
By Angus Liu During a heated discussion around a potential GSK application for Jemerpli in a rare cancer type, a panel of the FDA's external advisers largely took the middle ground between the company and the regulatory agency. |
By Frank Diamond Enrollment in Medicare Advantage has exploded over the past 15 years, a new study shows. However, the researchers warn that payment policy hasn't kept up with the times. |
By Teresa Carey This week on "The Top Line," we discuss which companies made the list of the top 10 pharma M&A deals of 2022 and what was at stake last year. We also talk about what last year's biggest deal means for M&A activity this year. |
By Max Bayer,Gabrielle Masson Bayer plucks former Roche pharma CEO Anderson to be new leader. Astellas promotes strategy head to CEO. White House OSTP leader to depart. |
By Angus Liu Astellas has named a new CEO to "go on the aggressive" in 2023. Eisai has recorded the first sales of its Alzheimer's disease drug Leqembi. Mitsubishi shuts down Canadian COVID vaccine maker Medicago. And more. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss which companies made the list of the top 10 pharma M&A deals of 2022 and what was at stake last year. We also talk about what last year's biggest deal means for M&A activity this year. |
|
|---|
|
|
|
March 14-15, 2023 | San Francisco, CA Uncover flexible partnership models, licensing deals, M&A opportunities, and innovative deal structures to maximize potential and ensure a successful and profitable collaboration. Register today to secure our lowest rates!
|
|
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperThis paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
